PUBLICATION
Lipid-modulate activity of Cichorium glandulosum Boiss.et Huet polysaccharide in nonalcoholic fatty liver disease larval zebrafish model
- Authors
- Li, M., Ma, J., Ahmad, O., Cao, Y., Wang, B., He, Q., Li, J., Yin, H., Zhang, Y., He, J., Shang, J.
- ID
- ZDB-PUB-181130-1
- Date
- 2018
- Source
- Journal of Pharmacological Sciences 138(4): 257-262 (Journal)
- Registered Authors
- Keywords
- Cichorium glandulosum Boiss.et Huet, Lipid-lowering, Non-alcoholic fatty liver disease, Polysaccharides, Zebrafish
- MeSH Terms
-
- Animals
- Asteraceae*
- Disease Models, Animal
- Hypolipidemic Agents/pharmacology
- Hypolipidemic Agents/therapeutic use*
- Larva
- Lipid Metabolism/drug effects
- Non-alcoholic Fatty Liver Disease/drug therapy*
- Non-alcoholic Fatty Liver Disease/genetics
- Non-alcoholic Fatty Liver Disease/metabolism
- Phytotherapy
- Polysaccharides/pharmacology
- Polysaccharides/therapeutic use*
- Transcriptome/drug effects
- Zebrafish
- PubMed
- 30482436 Full text @ J. Pharmacol. Sci.
Citation
Li, M., Ma, J., Ahmad, O., Cao, Y., Wang, B., He, Q., Li, J., Yin, H., Zhang, Y., He, J., Shang, J. (2018) Lipid-modulate activity of Cichorium glandulosum Boiss.et Huet polysaccharide in nonalcoholic fatty liver disease larval zebrafish model. Journal of Pharmacological Sciences. 138(4):257-262.
Abstract
Nonalcoholic fatty liver disease (NAFLD)1 is the most common chronic liver disease worldwide. Cichorium glandulosum Boiss.et Huet (CG) is a common traditional Uighur medicine, and it has been widely used as active therapy on various hepatic diseases. Recently, lipid-lowering effect has been revealed on CG. Polysaccharides are principal component of CG which could be the possible lipid-lowering compound in CG. In this study, extraction and purification of CG polysaccharides (CGP) was performed, and the lipid regulation effect of CGP was investigated on NAFLD zebrafish model. The results showed that CGP significantly decreased the levels of TC, TG, and decreased the mRNA expression of srebf-1, and fas, increased the expression of pparab. The findings suggest that the lipid-lowering effects of CGP mainly depend on facilitation of lipolysis (mainly beta-oxidation) or inhibition of lipogenesis. Furthermore, CGP could prevent and causes the regression of steatosis in NAFLD via its lipid metabolism regulation effect.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping